Lipid nanoparticle formulations and compositions

Targeted lipid nanoparticles with ionizable cationic lipids and antibody-binding domains address off-target delivery and toxicity issues, enhancing cytoplasmic delivery efficiency and reducing liver accumulation, thus improving nucleic acid delivery efficacy.

JP2026520518APending Publication Date: 2026-06-23CAPSTAN THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
CAPSTAN THERAPEUTICS INC
Filing Date
2024-05-31
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Current lipid nanoparticle (LNP) compositions face challenges with off-target delivery, low efficiency of nucleic acid release into the cytoplasm, and toxicity associated with lipid accumulation, particularly in tissues like the liver.

Method used

Development of lipid nanoparticles (LNPs) and formulations that include targeted LNPs (tLNPs) with ionizable cationic lipids and antibody-derived antigen-binding domains to specifically target tissues or cell types, enhancing cytoplasmic delivery efficiency and reducing off-target accumulation.

Benefits of technology

The improved formulations achieve higher transfection rates and expression levels of nucleic acids in targeted cells, while minimizing liver uptake and toxicity, thereby increasing the therapeutic efficacy of nucleic acid delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026520518000094
    Figure 2026520518000094
  • Figure 2026520518000095
    Figure 2026520518000095
  • Figure 2026520518000096
    Figure 2026520518000096
Patent Text Reader

Abstract

A composition of lipid nanoparticles (LNPs) comprising ionizable cationic lipids, phospholipids, sterols, and PEG-lipids (unfunctionalized and optionally functionalized) is disclosed. The functionalized PEG-lipids can be conjugated with binding sites to create target LNPs (tLNPs). The disclosed tLNPs preferentially deliver nucleic acid molecules or other load payloads to cells expressing cell surface antigens recognized by the binding site of the tLNP and are better tolerated than LNPs and tLNPs containing ionizable cationic lipids found in commercially available pharmaceuticals containing LNPs.
Need to check novelty before this filing date? Find Prior Art